SALT LAKE CITY, May 29, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today published in Nature Genetics ...
(MENAFN- GlobeNewsWire - Nasdaq) Published open-access today in Nature Genetics,“High-resolution genome-wide mapping of chromosome-arm-scale truncations induced by CRISPR–Cas9 editing” identifies ...
For a biotech like Recursion Pharmaceuticals (NASDAQ: RXRX) that aims to use artificial intelligence (AI) and petabytes of data as tools for drug discovery and development, computing power is a key ...
Eli Lilly is a safer way to capitalize on AI-driven drug discovery.
Artificial intelligence (AI)-based drug developer Recursion said it has completed the fastest supercomputer to be wholly owned and operated by any pharmaceutical company worldwide, using technology ...
Nvidia will help Recursion build a massive supercomputer. This will be used its for AI-driven drug discovery efforts. It may be the first of several moves to empower its platform. With the help of its ...
After a year defined by pipeline cuts, the departure of its CEO and layoffs, Exscientia will merge into Recursion, creating one company that has 10 clinical readouts to look forward to over the next ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback